Key Points o ¢ o Crescent Point Energy's shareholder-friendly nature and potential to benefit from an oil price rebound have Wall Street unanimously bullish. All seven analysts that actively follow biotech company Ardelyx have a buy rating, and the $12.25 consensus target points to about 50% upside over the next 12 months. EV manufacturer VinFast faces an uphill battle against competitors, but its positioning in every SUV segment could make it a viable option for consumers — and a comeback stock worth watch ...